PROM1 and familial pancreatic carcinoma: Moreover, new data emerged showing that the number of CD133+/CD44+/CD24+ cells, CD133+ precursors were reduced in a pancreatic cancer xenograft model following metronomic cyclophosphamide treatment by increasing thrombospondin-1 [35].